一种用于检测胰腺癌症的生物标志物小组
A Biomarker Panel for the Detection of Pancreatic Cancer.
摘要(中文译文)
胰腺癌是一种侵袭性恶性肿瘤，生存率低。大多数患者在晚期或转移阶段才被诊断，因为早期疾病通常无症状且缺乏有效的筛查工具。我们评估了一种由血清CA19-9联合血浆蛋白ITIH3和CEACAM1组成的三标志物模型用于胰腺导管腺癌（PDAC）检测。方法：从649名参与者（250例PDAC病例和399例对照）中收集配对的血浆和血清样本。使用高比表面积磁性共价有机框架（COF）聚合物富集血浆蛋白。使用Tosoh Bioscience免疫分析法测定血清CA19-9。标志物组合使用基于径向的SVM进行训练，采用重复10折交叉验证，使用预留的训练样本集。所推导的模型连同对应于训练样本中95%灵敏度的固定截断值，使用盲法样本集进行独立验证。结果：在独立盲法验证中，血清CA19-9联合血浆ITIH3和CEACAM1的组合面板达到了0.917的AUC，表明该三标志物面板在区分PDAC与对照方面保持了强劲性能。在预设阈值下，三标志物面板的特异性为53.3%（95% CI：46.8-59.7%），显著优于单独CA19-9的14.5%（95% CI：10.4-19.7%）。结论：在独立盲法验证中，将血浆ITIH3和CEACAM1与血清CA19-9联合使用大幅提高了PDAC的诊断性能，与单独血清CA19-9相比，在保持95%灵敏度的同时实现了高特异性。这些发现支持在更大规模的多中心研究中进一步验证该三标志物面板作为潜在的PDAC监测和检测方法。
Abstract
: Pancreatic cancer is an aggressive malignancy with poor survival. Most patients are diagnosed at advanced or metastatic stages because early disease is often asymptomatic and effective screening tools are lacking. We evaluated a three-marker model comprising serum CA19-9 in combination with the plasma proteins ITIH3 and CEACAM1 for pancreatic ductal adenocarcinoma (PDAC) detection. : Matched plasma and serum samples were collected from 649 participants (250 PDAC cases and 399 controls). Plasma proteins were enriched using high-surface area magnetic covalent organic framework (COF) polymers. Serum CA19-9 was measured using the Tosoh Bioscience immunoassay. The marker panel was trained using a radial-based SVM with repeated 10-fold cross-validation using a set-aside training sample set. The derived model along with a fixed cutoff corresponding to 95% sensitivity in training samples were independently validated using a blinded sample set. : In the independent blinded validation, the combined panel of serum CA19-9 with plasma ITIH3 and CEACAM1 achieved an AUC of 0.917 indicating that the three-marker panel maintained strong performance in distinguishing PDAC from controls. At the prefixed threshold, the three-marker panel had a specificity of 53.3% (95% CI: 46.8-59.7%), significantly outperforming CA19-9 alone at 14.5% (95% CI: 10.4-19.7%). : In independently blinded validation, combining plasma ITIH3 and CEACAM1 with serum CA19-9 substantially improved diagnostic performance for PDAC, achieving high specificity while maintaining 95% sensitivity compared with serum CA19-9 alone. These findings support further validation of this three-marker panel as a potential PDAC monitoring and detection approach in larger, multicenter studies.
如何引用
AMA
Yuefan Wang, Yuanyu Huang, Tung-Shing M Lih, Christine Worthington, Zhenyu Sun, Lori J Sokoll, et al. A Biomarker Panel for the Detection of Pancreatic Cancer.. Cancers. 2026; doi:10.3390/cancers18091397.
APA
Yuefan Wang, Yuanyu Huang, Tung-Shing M Lih, Christine Worthington, Zhenyu Sun, Lori J Sokoll, et al (2026). A Biomarker Panel for the Detection of Pancreatic Cancer.. Cancers. https://doi.org/10.3390/cancers18091397
GB/T 7714
Yuefan Wang, Yuanyu Huang, Tung-Shing M Lih, Christine Worthington, Zhenyu Sun, Lori J Sokoll, et al. A Biomarker Panel for the Detection of Pancreatic Cancer.[J]. Cancers, 2026 doi:10.3390/cancers18091397.
在 PubMed增强版 阅读全文
翻译全文 · AI 文献问答 · PDF 原文下载 · 引用导出